Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 4/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 3/20 | 0.38 |
| ▸ | KAT5 | Q92993 | 3/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | KAT7 | O95251 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2276039 | 0.84 | BCAT2 (0.38) | SUCNR1 | |
| SCHEMBL2277167 | 0.83 | DHODH (0.37) | SUCNR1KMO | |
| SCHEMBL2271773 | 0.80 | TTR (0.37) | SCN9ASUCNR1 | |
| Trifluoroacetic Acid SCHEMBL2279006 | 0.79 | SUCNR1 (0.51) | SUCNR1 | |
| SCHEMBL2277088 | 0.77 | PDE4A (0.42) | — | |
| SCHEMBL2274256 | 0.75 | PDE4D (0.40) | — | |
| SCHEMBL2272544 | 0.72 | PDE4A (0.41) | — | |
| SCHEMBL12370778 | 0.72 | SUCNR1 (0.49) | SUCNR1 | |
| SCHEMBL21722955 | 0.72 | SCN9A (0.43) | SCN9A | |
| SCHEMBL2281964 | 0.70 | HTR2C (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575364-B2 | Modulators of serotonin receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-05 | — | — | US | claimed |
| US-20110207709-A1 | MODULATORS OF SEROTONIN RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | claimed |
| WO-2010059390-A1 | MODULATORS OF SEROTONIN RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-27 | — | — | WO | claimed |
| US-8957059-B2 | Modulators of serotonin receptors | JANSSEN PHARMACEUTICA NV (BG) | 2015-02-17 | — | — | US | disclosed |
| US-20140038934-A1 | MODULATORS OF SEROTONIN RECEPTORS | JANSSEN PHARMACEUTICA NV (US) | 2014-02-06 | — | — | US | disclosed |
| US-8575364-B2 | Modulators of serotonin receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-05 | — | — | US | disclosed |
| US-20110207709-A1 | MODULATORS OF SEROTONIN RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | disclosed |
| WO-2010059390-A1 | MODULATORS OF SEROTONIN RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038934-A1 | MODULATORS OF SEROTONIN RECEPTORS | HTR1A, HTR2A, HTR6 | GRIN2B 92/4885KAT6A 2433/4885KAT5 4745/4885 |
| US-20110207709-A1 | MODULATORS OF SEROTONIN RECEPTOR | HTR1A, HTR6, HTR2A | GRIN2B 76/4885KAT6A 2303/4885KAT5 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.